Tevogen Inc. (TVGNW) stock
TVGNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as TVGN
$0.09+0.01 (+18.24%)
Close on Oct 30, 2026Market cap $38.42MP/E –Yield –
Tevogen EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Tevogen's EPS for the twelve months ending Jun 30, 2026 was -$6.98. For fiscal 2025 it was -$8.08.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.08 | – |
| FY2024 | Dec 31, 2024 | -$3.50 | – |
| FY2023 | Dec 31, 2023 | -$122.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.52 | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.61 | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.35 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.50 | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.71 | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.25 | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.50 | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.00 | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.00 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.50 | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.00 | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.00 | – |
| Q1 FY2022 | Mar 31, 2022 | $0.00 | – |
| Q3 FY2021 | Sep 30, 2021 | $0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics